The Ginkgo biloba extract EGb 761 ® and its main constituent flavonoids and ginkgolides increase extracellular dopamine levels in the rat prefrontal cortex: RESEARCH PAPER

British Journal of Pharmacology

Volumn 159, Issue 3, 2010, Pages 659-668

  Yoshitake, T ^a   Yoshitake, S ^a   Kehr, J ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Cognitive function; Dopamine; Ginkgo biloba; Microdialysis; Monoamines; Noradrenaline; Prefrontal cortex; Serotonin

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; DOPAMINE; FLAVANOID; GINKGO BILOBA EXTRACT; GINKGOLIDE; HOMOVANILLIC ACID; MONOAMINE; NORADRENALIN; SEROTONIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; COGNITION; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; DOPAMINERGIC TRANSMISSION; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; ELECTROCHEMISTRY; FLUORESCENCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; METABOLITE; MICRODIALYSIS; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE;

3,4-DIHYDROXYPHENYLACETIC ACID; ANIMALS; CORPUS STRIATUM; CYCLOPENTANES; DOPAMINE; FLAVONOIDS; FURANS; GINKGO BILOBA; GINKGOLIDES; HOMOVANILLIC ACID; MALE; MICRODIALYSIS; PLANT EXTRACTS; PREFRONTAL CORTEX; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN;

EID: 76449091140     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2009.00580.x     Document Type: Article

References (71)

1. Abdel-Kader R, Hauptmann S, Keil U, Scherping I, Leuner K, Eckert A et al. (2007). Stabilization of mitochondrial function by Ginkgo biloba extract (EGb 761). Pharmacol Res 56 : 493 502.
2. Ahlemeyer B, Krieglstein J (2003). Neuroprotective effects of Ginkgo biloba extract. Cell Mol Life Sci 60 : 1779 1792.
3. Ahmad M, Saleem S, Ahmad AS, Yousuf S, Ansari MA, Khan MB et al. (2005). Ginkgo biloba affords dose-dependent protection against 6-hydroxydopamine- induced parkinsonism in rats: neurobehavioural, neurochemical and immunohistochemical evidences. J Neurochem 93 : 94 104.
4. Alexander SPH, Mathie A, Peters JA (2008). Guide to receptors and channels (GRAC), 3rd edition. Br J Pharmacol 153 (Suppl. 2 S1 S209.
5. Andrieu S, Gillette S, Amouyal K, Nourhashemi F, Reynish E, Ousset PJ et al. (2003). EPIDOS study. Association of Alzheimer's disease onset with Ginkgo biloba and other symptomatic cognitive treatments in a population of women aged 75 years and older from the EPIDOS study. J Gerontol A Biol Sci Med Sci 58 : 372 377.
6. Baker GB, Reynolds GP (1989). Biogenic amines and their metabolites in Alzheimer's disease: noradrenaline, 5-hydroxytryptamine and 5-hydroxyindole-3- acetic acid depleted in hippocampus but not in substantia innominata. Neurosci Lett 100 : 335 339.
7. Bartus RT, Dean RL 3rd., Beer B, Lippa AS (1982). The cholinergic hypothesis of geriatric memory dysfunction. Science 217 : 408 414.
8. Birks J, Grimley Evans J (2007). Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev (2 CD003120.
9. Blecharz-Klin K, Piechal A, Joniec I, Pyrzanowska J, Widy-Tyszkiewicz E (2009). Pharmacological and biochemical effects of Ginkgo biloba extract on learning, memory consolidation and motor activity in old rats. Acta Neurobiol Exp (Wars) 69 : 217 231.
10. Bowen DM, Davison AN (1986). Biochemical studies of nerve cells and energy metabolism in Alzheimer's disease. Br Med Bull 42 : 75 80.
11. Brozoski TJ, Brown RM, Rosvold HE, Goldman PS (1979). Cognitive deficit caused by regional depletion of dopamine in prefrontal cortex of rhesus monkey. Science 205 : 929 932.
12. Brunello N, Racagni G, Clostre F, Drieu K, Braquet P (1985). Effects of an extract of Ginkgo biloba on noradrenergic systems of rat cerebral cortex. Pharmacol Res Commun 17 : 1063 1072.
13. Castner SA, Goldman-Rakic PS (2004). Enhancement of working memory in aged monkeys by a sensitizing regimen of dopamine D1 receptor stimulation. J Neurosci 24 : 1446 1450.
14. Chan PC, Xia Q, Fu PP (2007). Ginkgo biloba leave extract: biological, medicinal, and toxicological effects. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 25 : 211 244.
15. Chatterjee SS, Kondratskaya EL, Krishtal OA (2003). Structure-activity studies with Ginkgo biloba extract constituents as receptor-gated chloride channel blockers and modulators. Pharmacopsychiatry 36 (Suppl. 1 S68 S77.
16. Coyle JT, Price DL, DeLong MR (1983). Alzheimer's disease: a disorder of cortical cholinergic innervation. Science 219 : 1184 1190.
17. Cross AJ (1990). Serotonin in Alzheimer-type dementia and other dementing illnesses. Ann N Y Acad Sci 600 : 405 415.
18. Cross AJ, Crow TJ, Perry EK, Perry RH, Blessed G, Tomlinson BE (1981). Reduced dopamine-beta-hydroxylase activity in Alzheimer's disease. Br Med J 282 : 93 94.
19. DeFeudis FV (2003). A brief history of EGb 761 and its therapeutic uses. Pharmacopsychiatry 36 (Suppl. 1 S2 S7.
20. DeFeudis FV, Drieu K (2000). Ginkgo biloba extract (EGb 761) and CNS functions: basic studies and clinical applications. Curr Drug Targets 1 : 25 58.
21. DeKosky ST, Furberg CD (2008). Turning over a new leaf: Ginkgo biloba in prevention of dementia? Neurology 70 : 1730 1731.
22. DeKosky ST, Williamson JD, Fitzpatrick AL, Kronmal RA, Ives DG, Saxton JA et al. (2008). Ginkgo biloba for prevention of dementia. A randomized controlled trial. JAMA 300 : 2253 2262.
23. Dodge HH, Zitzelberger T, Oken BS, Howieson D, Kaye J (2008). A randomized placebo-controlled trial of Ginkgo biloba for the prevention of cognitive decline. Neurology 70 : 1809 1817.
24. Dringenberg HC (2000). Alzheimer's disease: more than a 'cholinergic disorder' - evidence that cholinergic-monoaminergic interactions contribute to EEG slowing and dementia. Behav Brain Res 115 : 235 249.
25. Fehske CJ, Leuner K, Müller WE (2009). Ginkgo biloba extract (EGb761) influences monoaminergic neurotransmission via inhibition of NE uptake, but not MAO activity after chronic treatment. Pharmacol Res 60 : 68 73.
26. Francis PT (1996). Pyramidal neurone modulation: a therapeutic target for Alzheimer's disease. Neurodegeneration 5 : 461 465.
27. Goldman-Rakic PS (1995). Cellular basis of working memory. Neuron 14 : 477 485.
28. Goldman-Rakic PS, Muly EC 3rd., Williams GV (2000). D(1) receptors in prefrontal cells and circuits. Brain Res Brain Res Rev 31 : 295 301.
29. Heads JA, Hawthorne RL, Lynagh T, Lynch JW (2008). Structure-activity analysis of ginkgolide binding in the glycine receptor pore. J Neurochem 105 : 1418 1427.
30. Hertel P, Nomikos GG, Svensson TH (1999). Idazoxan preferentially increases dopamine output in the rat medial prefrontal cortex at the nerve terminal level. Eur J Pharmacol 371 : 153 158.
31. Huang SH, Duke RK, Chebib M, Sasaki K, Wada K, Johnston GA (2004). Ginkgolides, diterpene trilactones of Ginkgo biloba, as antagonists at recombinant alpha1beta2gamma2L GABAA receptors. Eur J Pharmacol 494 : 131 138.
32. Huguet F, Drieu K, Piriou A (1994). Decreased cerebral 5-HT1A receptors during ageing: reversal by Ginkgo biloba extract (EGb 761). J Pharm Pharmacol 46 : 316 318.
33. Huguet F, Tarrade T (1992). Alpha 2-adrenoceptor changes during cerebral ageing. The effect of Ginkgo biloba extract. J Pharm Pharmacol 44 : 24 27.
34. Kanowski S, Hoerr R (2003). Ginkgo biloba extract EGb 761 in dementia: intent-to-treat analyses of a 24-week, multi-center, double-blind, placebo-controlled, randomized trial. Pharmacopsychiatry 36 : 297 303.
35. ® in middle aged healthy volunteers. Data presented at the 14th Annual Symposium on Complementary Health Care, Exeter, 11-13 December 2007.
36. Kehr J (1999). Monitoring chemistry of brain microenvironment: biosensors, microdialysis and related techniques. Chapter 41. In : Windhorst U, Johansson H (eds). Modern Techniques in Neuroscience Research. Springer-Verlag GmbH : Heidelberg, Germany, pp. 1149 1198.
37. Kehr J, Yoshitake T (2006). Monitoring brain chemical signals by microdialysis. In : Grimes CA, Dickey EC, Pishko MV (eds). Encyclopedia of Sensors, Vol. 6. American Scientific Publishers : Valencia, CA, pp. 287 312.
38. Li Z, Prus AJ, Dai J, Meltzer HY (2009). Differential effects of M1 and 5-hydroxytryptamine1A receptors on atypical antipsychotic drug-induced dopamine efflux in the medial prefrontal cortex. J Pharmacol Exp Ther 330 : 948 955.
39. Mazza M, Capuano A, Bria P, Mazza S (2006). Ginkgo biloba and donepezil: a comparison in the treatment of Alzheimer's dementia in a randomized placebo-controlled double-blind study. Eur J Neurol 13 : 981 985.
40. Mehta MA, Riedel WJ (2006). Dopaminergic enhancement of cognitive function. Curr Pharm Des 12 : 2487 2500.
41. Meltzer HY, Huang M (2008). In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems. Prog Brain Res 172 : 177 197.
42. Müller U, von Cramon DY, Pollmann S (1998). D1- versus D2-receptor modulation of visuospatial working memory in humans. J Neurosci 18 : 2720 2728.
43. Napryeyenko O, Borzenko I, GINDEM-NP Study Group (2007). Ginkgo biloba special extract in dementia with neuropsychiatric features. A randomised, placebo-controlled, double-blind clinical trial. Arzneimittelforschung 57 : 4 11. (Pubitemid 46212982)
44. Osborne PG, O'Conner WT, Kehr J, Ungerstedt U (1990). In vivo characterisation of extracellular dopamine, GABA, and acetylcholine from the dorsolateral striatum of conscious freely-moving rats by chronic microdialysis. J Neurosci Methods 37 : 93 102.
45. Pardon MC, Joubert C, Perez-Diaz F, Christen Y, Launay JM, Cohen-Salmon C (2000). In vivo regulation of cerebral monoamine oxidase activity in senescent controls and chronically stressed mice by long-term treatment with Ginkgo biloba extract (EGb 761). Mech Ageing Dev 113 : 157 168.
46. Paspalas CD, Goldman-Rakic PS (2005). Presynaptic D1 dopamine receptors in primate prefrontal cortex: target-specific expression in the glutamatergic synapse. J Neurosci 25 : 1260 1267.
47. Paxinos G, Watson C (1997). The Rat Brain in Sterotaxic Coordinates. Academic Press : Sydney, Australia.
48. Phillips AG, Vacca G, Ahn S (2008). A top-down perspective on dopamine, motivation and memory. Pharmacol Biochem Behav 90 : 236 249.
49. Rojas P, Serrano-García N, Mares-Sámano JJ, Medina-Campos ON, Pedraza-Chaverri J, Ogren SO (2008). EGb761 protects against nigrostriatal dopaminergic neurotoxicity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine- induced Parkinsonism in mice: role of oxidative stress. Eur J Neurosci 28 : 41 50.
50. Rossetti ZL, Carboni S (2005). Noradrenaline and dopamine elevations in the rat prefrontal cortex in spatial working memory. J Neurosci 25 : 2322 2329.
51. Rossor M, Lversen LL (1986). Non-cholinergic neurotransmitter abnormalities in Alzheimer's disease. Br Med Bull 42 : 70 74.
52. Satvat E, Mallet PE (2009). Chronic administration of a Ginkgo biloba leaf extract facilitates acquisition but not performance of a working memory task. Psychopharmacology (Berl) 202 : 173 185.
53. Scripnikov A, Khomenko A, Napryeyenko O, GINDEM-NP Study Group (2007). Effects of Ginkgo biloba extract EGb 761 on neuropsychiatric symptoms of dementia: findings from a randomised controlled trial. Wien Med Wochenschr 157 : 295 300. (Pubitemid 47356252)
54. Shah ZA, Sharma P, Vohora SB (2003). Ginkgo biloba normalises stress-elevated alterations in brain catecholamines, serotonin and plasma corticosterone levels. Eur Neuropsychopharmacol 13 : 321 325.
55. Shin JC, Chen K, Ridd MJ, Seif I (2000). Ginkgo biloba abolishes aggression in mice lacking MAO A. Antioxid Redox Signal 2 : 467 471.
56. Stackman RW, Eckenstein F, Frei B, Kulhanek D, Nowlin J, Quinn JF (2003). Prevention of age-related spatial memory deficits in a transgenic mouse model of Alzheimer's disease by chronic Ginkgo biloba treatment. Exp Neurol 184 : 510 520.
57. Szasz BK, Lenkey N, Barth AM, Mike A, Somogyvari Z, Farkas O et al. (2008). Converging effects of Ginkgo biloba extract at the level of transmitter release, NMDA and sodium currents and dendritic spikes. Planta Med 74 : 1235 1239.
58. Taylor JE (1986). Neuromediator binding to receptors in the rat brain. The effect of chronic administration of Ginkgo biloba extract. (French). Presse Med 15 : 1491 1493.
59. Terry AV, Buccafusco JJ (2003). The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: recent challenges and their implications for novel drug development. J Pharmacol Exp Ther 306 : 821 827.
60. Terry RD (1994). Neuropathological changes in Alzheimer disease. Prog Brain Res 101 : 383 390.
61. Thomas DN, Nutt DJ, Holman RB (1998). Sertraline, a selective serotonin reuptake inhibitor modulates extracellular noradrenaline in the rat frontal cortex. J Psychopharmacol 12 : 366 370.
62. Vellas B, Andrieu S, Ousset PJ, Ouzid M, Mathiex-Fortunet H, GuidAge Study Group (2006). The GuidAge study: methodological issues. A 5-year double-blind randomized trial of the efficacy of EGb 761 for prevention of Alzheimer disease in patients over 70 with a memory complaint. Neurology 67 (Suppl. 3 S6 S11.
63. Wang Y, Wang L, Wu J, Cai J (2006). The in vivo synaptic plasticity mechanism of EGb 761-induced enhancement of spatial learning and memory in aged rats. Br J Pharmacol 148 : 147 153.
64. Weikop P, Kehr J, Scheel-Krüger J (2004). The role of alpha1- and alpha2-adrenoreceptors on venlafaxine-induced elevation of extracellular serotonin, noradrenaline and dopamine levels in the rat prefrontal cortex and hippocampus. J Psychopharmacol 18 : 395 403.
65. White HL, Scates PW, Cooper BR (1996). Extracts of Ginkgo biloba leaves inhibit monoamine oxidase. Life Sci 58 : 1315 1321.
66. Williams GV, Goldman-Rakic PS (1995). Modulation of memory fields by dopamine D1 receptors in prefrontal cortex. Nature 376 : 572 575.
67. Wu WR, Zhu XZ (1999). Involvement of monoamine oxidase inhibition in neuroprotective and neurorestorative effects of Ginkgo biloba extract against MPTP-induced nigrostriatal dopaminergic toxicity in C57 mice. Life Sci 65 : 157 164.
68. Yeghiayan SK, Andersen SL, Baldessarini RJ (1997). Lack of effect of chronic clorgyline or selegiline on dopamine and serotonin transporters in rat caudate-putamen or nucleus accumbens septi. Neurosci Lett 236 : 147 150.
69. Yeh KY, Pu HF, Kaphle K, Lin SF, Wu LS, Lin JH et al. (2008). Ginkgo biloba extract enhances male copulatory behavior and reduces serum prolactin levels in rats. Horm Behav 53 : 225 231.
70. Yoshitake T, Kehr J, Yoshitake S, Fujino K, Nohta H, Yamaguchi M (2004a). Determination of serotonin, noradrenaline, dopamine and their metabolites in rat brain extracts and microdialysis samples by column liquid chromatography with fluorescence detection following derivatization with benzylamine and 1,2-diphenylethylenediamine. J Chromatogr B 807 : 177 183.
71. Yoshitake T, Yoshitake S, Fujino K, Nohta H, Yamaguchi M, Kehr J (2004b). High-sensitive liquid chromatographic method for determination of neuronal release of serotonin, noradrenaline and dopamine monitored by microdialysis in the rat prefrontal cortex. J Neurosci Methods 140 : 163 168.